Skip to content

The effect of melatonin supplementation on migraine

The effect of melatonin supplementation on symptoms of headache and CGRP in women with migraine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20121216011763N40
Enrollment
88
Registered
2019-12-15
Start date
2020-02-20
Completion date
Unknown
Last updated
2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Migraine. Condition 2: Migraine. Migraine Migraine

Interventions

Intervention 1: Intervention group: Daily melatonin 3 mg half an hour before bedtime for 8 weeks. Intervention 2: Control group: One placebo daily (50 mg starch) half an hour before bedtime for 8 week

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Women from the age of 18 to menopause Diagnosis of migraine by a neurologist Willing to work with the project

Exclusion criteria

Exclusion criteria: People with a history of overdose of analgesics according to IHS criteria for antidepressant abuse Pregnancy or breast-feeding History of significant complications or recent use of melatonin supplements Severe depression in the past year

Design outcomes

Primary

MeasureTime frame
Migraine symptoms (severity, frequency, duration of migraine). Timepoint: Week 0 and Week 8. Method of measurement: Questionnaire.;Serum levels of calcitonin-associated peptide (CGRP). Timepoint: Week 0 and Week 8. Method of measurement: Laboratory analysis (blood test).

Secondary

MeasureTime frame
Depression, stress, anxiety. Timepoint: week 0 and week 8. Method of measurement: DASS-21questionnaire.;Quality of Life in Migraine Patients. Timepoint: week 0 and week 8. Method of measurement: Migraine –Specific Quality of Life(MSQ)questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Moradi

Esfahan University of Medical Sciences

f.moradi224@gmail.com+98 31 1792 2110

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026